AIM ImmunoTech
Ocala, Florida, United States · Biotechnology, Healthcare, Health Care
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical tr
Key facts
- Headquarters
- Ocala, Florida, United States
- Employees
- 32
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (AIM)
- Website
- aimimmuno.com
- Company page
Recent activity at AIM ImmunoTech
- : SEC 8-K (7.01): The Company, AIM ImmunoTech Inc., issued a press release on November 5, 2026, along with a corporate presentation titled 'The Ampligen Opportunity.' This announcement covers forward-looking statements regarding Ampligen's potential to enhance clinical benefits, particularly in the treatment of pancreatic cancer. The Company discusses its business strategy and objectives, regulatory expectations, and the risks involved in pharmaceutical development. This filing serves to inform stakeholders about the Company’s recent developments and strategic direction.
- : SEC 8-K (1.01): On September 8-9, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements enabled the conversion of approximately $400,000 of a previously issued promissory note into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. This transaction was previously approved by the Company’s stockholders, aligning with compliance procedures under NYSE American regulations. The strategic implication of this conversion is expected to enhance liquidity and balance the Company’s capital structure effectively.
- : SEC 8-K (1.01): On September 3, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements involved the conversion of approximately $450,000 of a previously issued Promissory Note into 1,921,441 shares of the company's common stock at an average conversion price of $0.234 per share. Shareholder approval for this conversion was obtained prior, ensuring compliance with NYSE American requirements. The transaction will potentially enhance the company’s equity base and strengthen its financial position in light of future operational needs.
- : SEC 8-K (1.01): On August 31, 2026, AIM ImmunoTech Inc. entered into five exchange agreements with Streeterville Capital, LLC, which involved the conversion of approximately $1,224,341 of a prior Promissory Note dated February 16, 2024 into 5,065,840 shares of the Company's common stock at an average conversion price of approximately $0.24 per share. The conversion satisfied the Promissory Note in full, eliminating any remaining obligations. The agreements reflect a significant restructuring of the Company's debt and enhance its equity position as of September 3, 2026.
- : SEC 8-K (7.01): On August 11, 2026, AIM ImmunoTech Inc. provided a Regulation FD disclosure through an article published by Breaking Defense, authored by CEO Thomas K. Equels. The article discusses the potential of Ampligen (rintatolimod) as a broad-spectrum early-onset antiviral therapeutic for diseases such as Ebola and COVID-19. This disclosure highlights the strategic importance of military readiness and shares forward-looking statements about Ampligen's effectiveness and future clinical trials, although it clarifies that these statements involve risks and uncertainties. The content aims to inform the market about the drug's potential and the company's ongoing commitment to advancing its business strategy.
- : SEC 8-K (1.01):
- : SEC 8-K (1.02): On July 31, 2026, AIM ImmunoTech Inc. provided notice for the mutual termination of the Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026. The Company will not incur any termination penalties as a result of this termination. From April 1, 2025, to July 31, 2026, the Company sold a total of 3,200,736 shares of common stock, generating approximately $2.8 million in gross proceeds. Following this termination, AIM ImmunoTech has stated it will not issue or sell any additional shares under the Agreement prior to its termination, which has potential implications on its capital raising strategies going forward.
- : SEC 8-K (8.01): On June 15, 2026, AIM ImmunoTech Inc. announced that it received confirmation from NYSE Regulation on June 12, 2026, that the Company has regained compliance with the continued listing standards of the NYSE American LLC. This letter confirmed that AIM resolved deficiencies under Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide, leading to the removal of the '.BC' compliance indicator from its trading symbol. The firm will no longer be listed as a noncompliant issuer on the NYSE American's website, ensuring it remains subject to continued monitoring. This achievement highlights AIM's commitment to maintaining strong financial and governance standards moving forward.
- : SEC 8-K (1.01): On June 9, 2026, AIM ImmunoTech Inc. entered into a securities purchase agreement with institutional investors to issue a total of 2,554,119 shares of common stock at an offering price of $0.5189 per share, generating approximately $1.3 million in gross proceeds. The agreement also includes a concurrent private placement for 771,503 shares and warrants to purchase additional shares worth an estimated $5.3 million upon exercise. The offerings are set to close on June 10, 2026, pending customary closing conditions, with provisions for indemnification and termination included in the agreement. This strategic move aims to bolster the company's financial position and support future operations.
- : SEC 8-K (7.01): On June 4, 2026, AIM ImmunoTech Inc. provided a Regulation FD disclosure through the release of an on-demand video presentation that detailed the pre-clinical findings of its drug candidate Ampligen® (rintatolimod) for treating Ebola virus disease (EVD). This disclosure aimed to inform investors about the potential antiviral treatment capabilities of Ampligen®, and included additional resources like a press release (Exhibit 99.1) and an investor presentation slide deck (Exhibit 99.2). The presentation is accessible on their website, which highlights the Company’s ongoing research efforts into EVD, marking a significant strategic initiative as they seek to advance in the biotech space. This event underscores AIM ImmunoTech's commitment to transparency and investor engagement regarding its clinical developments.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
AIM ImmunoTech funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Post-IPO Equity | $2.4M |
| Feb 2024 | Seed | $3.3M |
| Apr 2018 | Pre-Seed | $26K |
| Feb 2017 | Pre-Seed | $18K |
| Sep 2016 | Pre-Seed | $33K |
Leadership
- David Chemerow, Member Board of Directors
- Jodie Pelz, Director of Accounting & Finance
- Ann, Director of Human Resources and Administration; Deputy Investor Relations Coordinator
- Stewart Appelrouth, Director
- William Mitchell, Director
- Thomas Equels, Executive Officer, Director
- Peter Rodino, Director
Verified email and direct lines for AIM ImmunoTech’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
AIM ImmunoTech files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
AIM ImmunoTech in the news
- AIM ImmunoTech Discusses Ampligen®’s Potential to - GlobeNewswire (Sep 30, 2026)
- AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire (Oct 05, 2026)
- AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire (Oct 01, 2026)
- AIM ImmunoTech Highlights Ampligen’s Potential Role in the - GlobeNewswire (Sep 22, 2026)
- AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire (Sep 09, 2026)
- AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays - GlobeNewswire (Oct 07, 2026)
- AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer - GlobeNewswire (Nov 05, 2026)
- AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - GlobeNewswire (Jun 15, 2026)
Companies similar to AIM ImmunoTech
- Retension Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Arbutus · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About AIM ImmunoTech: questions and answers
What does AIM ImmunoTech do?
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical tr
Where is AIM ImmunoTech headquartered?
AIM ImmunoTech is headquartered in Ocala, Florida, United States.
How many employees does AIM ImmunoTech have?
AIM ImmunoTech has about 32 employees.
Has AIM ImmunoTech raised funding?
Yes. Fundz has recorded 5 funding events for AIM ImmunoTech. The most recent, Post-IPO Equity of $2.4M, was in May 2026.
What is the latest news on AIM ImmunoTech?
On Oct 20, 2025, SEC 8-K (7.01): The Company, AIM ImmunoTech Inc., issued a press release on November 5, 2026, along with a corporate presentation titled 'The Ampligen Opportunity.' This announcement covers forward-looking statements regarding Ampligen's potential to enhance clinical benefits, particularly in the tr
Is AIM ImmunoTech a public company?
Yes. AIM ImmunoTech is publicly traded under the ticker AIM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy